Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 3/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3390823 | 1.00 | PDE2A (0.56) | PDE2AHTR7ALDH1A1KMT2AMEN1 | |
| SCHEMBL3391066 | 0.86 | MEN1 (0.56) | PDE2AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL3391063 | 0.86 | MEN1 (0.56) | PDE2AALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL2821668 | 0.80 | NPC1 (0.59) | HTR7ALDH1A1KMT2AMEN1HSD11B1 | |
| SCHEMBL1972661 | 0.80 | NPC1 (0.59) | HTR7ALDH1A1KMT2AMEN1HSD11B1 | |
| SCHEMBL193622 | 0.80 | NPC1 (0.59) | HTR7ALDH1A1KMT2AMEN1HSD11B1 | |
| SCHEMBL24746300 | 0.79 | HTR7 (0.54) | PDE2AHTR7ALDH1A1KMT2AHSD11B1 | |
| SCHEMBL19321960 | 0.77 | ALDH1A1 (0.61) | HTR7ALDH1A1KMT2AGRM3TSHR | |
| SCHEMBL17850189 | 0.75 | HPGD (0.50) | PDE2AALDH1A1HSD11B1HTT | |
| SCHEMBL10194846 | 0.75 | GRM3 (0.62) | ALDH1A1KMT2AMEN1PKMGRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809620-B1 | NOVEL TETRAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2010-12-29 | — | — | EP | disclosed |
| US-20070299110-A1 | Novel Tetrazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate | ADDEX PHARMACEUTICALS SA (CH) | 2007-12-27 | — | — | US | disclosed |
| EP-1809620-A1 | NOVEL TETRAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharma SA (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048771-A1 | NOVEL TETRAZOLE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299110-A1 | Novel Tetrazole Derivatives as Positive Allosteric Modulators of Metabotropic Glutamate | GRM5, GRIK5, GRM1 | PDE2A 2648/4885HTR7 530/4885ALDH1A1 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.